Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Asset disposition
Appointed director
Quarterly results
Director departure

ACHILLION PHARMACEUTICALS INC (ACHN) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/19/2019 GN Achillion Shareholders Approve Agreement to be Acquired by Alexion
12/09/2019 GN Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting
11/29/2019 GN Rigrodsky & Long, P.A. Files Class Action Suit Against Achillion Pharmaceuticals, Inc.
11/19/2019 GN European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor
11/11/2019 GN Achillion Announces Clearance of Investigational New Drug Application for ACH-5228
11/07/2019 GN Achillion Reports Third Quarter 2019 Financial Results and Provides Corporate Update
11/06/2019 GN Achillion Announces Data Presentations at the 61st American Society of Hematology Annual Meeting
11/04/2019 GN Merger Investigation Alert: Halper Sadeh LLP Investigates Whether the Sale of These Companies is Fair to Shareholders – LPT, CISN, IPHS, ACHN
10/29/2019 GN SHAREHOLDER ALERT: WeissLaw LLP Reminds HLND, TNCB, ACHN, RARX Shareholders About Its Ongoing Investigations
10/23/2019 GN MERGER ALERT – ACHN, JAG, and ROAN: Levi & Korsinsky, LLP Notifies Investors of Investigations Concerning the Sale of these Companies
09/26/2019 GN Achillion to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference
09/25/2019 GN Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria
08/29/2019 GN Achillion to Present at the Baird 2019 Global Healthcare Conference
06/13/2019 GN Achillion to Present at the JMP Securities Life Sciences Conference
06/10/2019 GN Achillion Announces Upcoming Scientific Presentation at the 24th Congress of the European Hematology Association
05/17/2019 GN Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Combination Trial with Eculizumab at The New Era of Aplastic Anemia and PNH Meeting
05/14/2019 GN Achillion Granted Twentieth Patent for Factor D Portfolio
05/09/2019 GN Achillion Reports First Quarter 2019 Financial Results
04/03/2019 GN Achillion Announces Enrollment Milestone in Phase 2 Trials for C3 Glomerulopathy
03/27/2019 GN Achillion Announces Completion of Enrollment in Phase 2 PNH Combination Trial
03/08/2019 GN Achillion to Present at the Barclays Global Healthcare Conference
03/07/2019 GN Achillion Reports Fourth Quarter and Full Year 2018 Financial Results
02/21/2019 GN Achillion Pharmaceuticals Expands Operations and Clinical Development into Philadelphia Area Office Market
02/19/2019 GN Achillion to Present at the SVB Leerink 8th Annual Global Healthcare Conference
02/11/2019 GN Achillion Appoints Brian Di Donato as Chief Financial Officer
01/03/2019 GN Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors
12/17/2018 GN Achillion Reports Positive Interim Data for ACH-4471 Phase 2 Trials and Provides Clinical Development Strategy Update
12/10/2018 GN Achillion Interim Clinical Trial Data and Strategic Update Planned for Dec 17th, 2018
11/07/2018 GN Achillion Reports Third Quarter 2018 Financial Results
10/17/2018 GN Investor Expectations to Drive Momentum within SunOpta, Acorda Therapeutics, Sapiens International Corporation N.V, The Descartes Systems Group, Achillion Pharmaceuticals, and CSS Industries — Discovering Underlying Factors of Influence
09/25/2018 GN Achillion to Present at the Leerink Partners Roundtable Series
09/10/2018 GN Achillion Appoints Paul Firuta Chief Operating Officer
08/30/2018 GN Achillion to Present at the Baird 2018 Global Healthcare Conference
08/21/2018 GN Achillion Appoints Dr. Steven Zelenkofske as Chief Medical Officer and Further Strengthens Clinical Development Team
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy